Related Experiment Video

Updated: May 5, 2026

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.5K

Managing comorbid complications in patients with common variable immunodeficiency

Mark Ballow1

  • 1Division of Allergy and Immunology, Women & Children's Hospital of Buffalo and SUNY Buffalo, School of Medicine, Buffalo, New York; Division of Allergy and Immunology, Department of Pediatrics, University of South Florida, Children's Research Institute, St. Petersburg, Florida.

Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|November 26, 2013
PubMed

Insights

This review explores secondary complications in common variable immunodeficiency (CVID), highlighting how understanding clinical phenotypes and biomarkers aids in identifying and treating patients with CVID and associated conditions.

Area of Science:

  • Immunology
  • Clinical Medicine

Background:

  • Common variable immunodeficiency (CVID) is a primary immunodeficiency characterized by impaired antibody production.
  • Secondary complications significantly impact the morbidity and mortality of CVID patients.

Purpose of the Study:

  • To review the literature on identifying and treating secondary complications in CVID.
  • To understand the role of clinical phenotypes and biomarkers in CVID management.

Main Methods:

  • Literature search of PubMed and Ovid MEDLINE databases.
  • Selection of articles focusing on comorbid conditions in CVID and their management.
  • Emphasis on clinical phenotypes and biomarkers for patient identification and management.

Main Results:

  • Noninfective complications enhance understanding of CVID pathogenesis and treatment.
  • Clinical phenotypes are linked to varying survival risks in CVID patients.
  • Biomarkers and phenotypes aid in defining CVID patient groups.

Conclusions:

  • Ongoing research into CVID phenotypes and biomarkers can improve identification and targeted treatment of secondary complications.
  • Enhanced knowledge of outcomes will facilitate more appropriate and effective patient management.
  • Future research aims to refine treatment strategies for CVID patients at risk of complications.
Abstract

More Related Videos

Simultaneous Quantification of T-Cell Receptor Excision Circles TRECs and K-Deleting Recombination Excision Circles KRECs by Real-time PCR14:14

Simultaneous Quantification of T-Cell Receptor Excision Circles TRECs and K-Deleting Recombination Excision Circles KRECs by Real-time PCR

Published on: December 6, 2014

16.3K
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

11.4K

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.8K
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.2K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
657
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.3K
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
361
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
548